These mutations consisted of 19 KRAS (24.7%), 10 EGFR (13%), five BRAF (6.5%), four PIK3CA (5.2%), one HER2 (1.3%), one HER4 (2.2%) and none for HER3. mEGFR, mBRAF and mHER2 were present exclusively in adenocarcinomas while mKRAS were more frequent in adenocarcinoma and large cell histologies. This evidence concerns the gene KRAS and adenocarcinoma.